subject: Aarkstore Enterprise--- Pharmaceutical Pricing, Reimbursement & Distribution In Poland, 2010 And B [print this page] Poland, the largest market in central and eastern Europe, has weathered the global economic downturn better than many other countries across the continent. Its USD 6+ billion pharmaceutical sector (at ex-factory prices) in particular has been remarkably resilient, with value growth in each of the past three years exceeding 9%, the second highest increase in the EU. Traditionally a market dominated by generics, imported originator brands now account for 72% of sales Yet pricing and reimbursement processes are far from transparent, and if OTCs are included, patients are asked to pay 68% of the medicines bill out-of-pocket, a very high share for a country with a comprehensive social health insurance system.
Poland is full of surprises. Be better prepared and informed to tackle this dynamic emerging market. Pharmaceutical Pricing, Reimbursement & Distribution in Poland, 2010 and Beyond will provide you with clear, comprehensive, fully-researched and up-to-date information, including the following:
*
How introductory prices are set.
*
The complex forms of reimbursement explained with many illustrative examples.
*
Alternatives to appearing on the positive list.
*
How manufacturer discounts lessen the co-payment burden and drive market share.
*
Therapeutic programmes for high-cost speciality drugs.
*
Which products have maximum acquisition prices set for hospitals.
*
First 12 months experience with AstraZenecas direct-to-pharmacy distribution model, the only form of exclusive DTP in Europe outside the UK.
*
Two-way flow in one of Europes newest and fastest-growing parallel trade scenes.
*
Reforms to P&R the government is now proposing and what these might mean for the pharmaceutical industry.
